Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
499.3 INR | +1.30% | +5.23% | +2.24% |
May. 06 | Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024 | |
May. 03 | Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With a 2024 P/E ratio at 25.76 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.24% | 531M | D+ | ||
+43.64% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.58% | 351B | C+ | ||
+19.72% | 328B | B- | ||
+8.78% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.03% | 167B | C+ | ||
+6.13% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AARTIDRUGS Stock
- Ratings Aarti Drugs Limited